Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical development for cancer

CAR-T Digest - August 2020

Weekly Digest - April 2026

08 April 2026: Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical development for cancer

Sidewinder Therapeutics has secured $137 million in an oversubscribed Series B financing, providing significant momentum to advance its next-generation bispecific ADC platform toward clinical development
The financing was co-led by Frazier Life Sciences and Novartis Venture Fund, alongside a strong syndicate of new and existing investors, underscoring growing confidence in the company’s differentiated approach
With this funding, Sidewinder aims to accelerate the development of its precision bispecific ADCs, which are designed to target tumor-specific receptor co-complexes to enhance selectivity, internalization, and drug delivery to cancer cells
The company’s pipeline is focused on difficult-to-treat solid tumors, including lung and head and neck squamous cell carcinomas, as well as gastrointestinal cancers such as colorectal cancer, where unmet need remains high
With strong investor support and an innovative scientific approach, Sidewinder plans to move its lead program into clinical development in 2027, positioning the company as a leader in the next generation of ADC innovation